NCT02202525

Brief Summary

The main purpose of this prospective, multicentre, french observational study is to analyse the evolution of pulse pressure (PP) and to identify its prognostic factors in hypertensive patients three months after initiation of a new hypertensive therapy. The PP is defined as the difference between systolic blood pressure (SBP) and diastolic blood pressure (DBP).

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2,148

participants targeted

Target at P75+ for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2001

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2002

Completed
12.4 years until next milestone

First Submitted

Initial submission to the registry

July 28, 2014

Completed
1 day until next milestone

First Posted

Study publicly available on registry

July 29, 2014

Completed
Last Updated

July 29, 2014

Status Verified

July 1, 2014

Enrollment Period

1.2 years

First QC Date

July 28, 2014

Last Update Submit

July 28, 2014

Conditions

Hypertension

Outcome Measures

Primary Outcomes (2)

  • Changes from baseline in pulse pressure

    Up to 3 months after start of treatment

  • Number of patients with adverse drug reactions

    Up to 3 months after start of treatment

Study Arms (1)

Essential arterial hypertension

Patients with essential arterial hypertension needing a new antihypertensive therapy

Drug: Micardis®Drug: Other hypertensives

Interventions

Micardis®DRUG
Also known as: Telmisartan
Essential arterial hypertension
Other hypertensivesDRUG
Essential arterial hypertension

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with essential hypertenstion treated by private or hospital cardiologists

You may qualify if:

  • Patients with essential arterial hypertension needing a new antihypertensive therapy
  • A patient was included by the physician only if he/she had agreed after being informed about the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Hypertension

Interventions

Telmisartan

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular Diseases

Intervention Hierarchy (Ancestors)

Biphenyl CompoundsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsBenzimidazolesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic Compounds

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 28, 2014

First Posted

July 29, 2014

Study Start

January 1, 2001

Primary Completion

March 1, 2002

Last Updated

July 29, 2014

Record last verified: 2014-07